Shinichi Hasako

Title: Innovations by Shinichi Hasako in Antitumor Agents

Introduction

Shinichi Hasako is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of oncology through his innovative work on antitumor agents. With a total of 2 patents, Hasako's inventions focus on targeting specific mutations in the epidermal growth factor receptor (EGFR), which are crucial in the treatment of malignant tumors.

Latest Patents

Hasako's latest patents include a selective inhibitor of exon 20 insertion mutant EGFR. This antitumor agent comprises a compound selected from a group of compounds described in the specification, aimed at treating patients with malignant tumors expressing EGFR with exon 20 insertion mutations. Another significant patent is for an exon 18 and/or exon 21 mutant EGFR selective inhibitor. This agent is designed for treating patients with at least one mutation selected from the G719X mutation of exon 18, E709X mutation of exon 18, and L861X mutation of exon 21. The antitumor agent includes (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof.

Career Highlights

Shinichi Hasako is currently associated with Taiho Pharmaceutical Company Limited, where he continues to develop innovative solutions for cancer treatment. His work has been instrumental in advancing therapeutic options for patients with specific genetic mutations.

Collaborations

Hasako collaborates with esteemed colleagues such as Kazutaka Miyadera and Yoshimi Aoyagi. Their combined expertise contributes to the development of effective antitumor agents.

Conclusion

Shinichi Hasako's contributions to the field of oncology through his patents on selective inhibitors highlight his commitment to improving cancer treatment. His innovative work continues to pave the way for advancements in targeted therapies.